Wall Street brokerages forecast that Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) will post earnings per share (EPS) of ($0.55) for the current quarter, according to Zacks. Zero analysts have provided estimates for Aeglea Bio Therapeutics’ earnings. Aeglea Bio Therapeutics posted earnings of ($0.41) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 34.1%. The firm is expected to issue its next quarterly earnings results on Thursday, March 22nd.
On average, analysts expect that Aeglea Bio Therapeutics will report full-year earnings of ($1.97) per share for the current year. For the next financial year, analysts expect that the business will post earnings of ($2.00) per share. Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Aeglea Bio Therapeutics.
Separately, Zacks Investment Research lowered shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th.
Shares of Aeglea Bio Therapeutics (NASDAQ:AGLE) traded up $0.10 on Friday, reaching $7.60. 100,461 shares of the company’s stock traded hands, compared to its average volume of 83,357. Aeglea Bio Therapeutics has a one year low of $2.81 and a one year high of $8.14. The firm has a market capitalization of $124.83 and a price-to-earnings ratio of -4.15.
In related news, CEO Anthony G. Quinn bought 8,288 shares of the stock in a transaction on Friday, December 8th. The shares were bought at an average cost of $4.96 per share, for a total transaction of $41,108.48. Following the completion of the transaction, the chief executive officer now owns 32,009 shares of the company’s stock, valued at approximately $158,764.64. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 27.00% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of AGLE. Vanguard Group Inc. grew its position in Aeglea Bio Therapeutics by 9.4% during the second quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock worth $579,000 after buying an additional 12,966 shares during the period. Jennison Associates LLC grew its position in shares of Aeglea Bio Therapeutics by 0.6% in the fourth quarter. Jennison Associates LLC now owns 1,393,439 shares of the biotechnology company’s stock valued at $7,539,000 after purchasing an additional 8,372 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of Aeglea Bio Therapeutics by 150.8% in the fourth quarter. Renaissance Technologies LLC now owns 32,100 shares of the biotechnology company’s stock valued at $174,000 after purchasing an additional 19,300 shares during the last quarter. Institutional investors own 47.63% of the company’s stock.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.